$NAOV
NanoVibronix, Inc.

2023 Q1 Form 10-Q Financial Statement

#000149315223017233 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $354.0K $272.0K
YoY Change 30.15% 172.0%
Cost Of Revenue $119.0K $166.0K
YoY Change -28.31% 453.33%
Gross Profit $235.0K $106.0K
YoY Change 121.7% 32.5%
Gross Profit Margin 66.38% 38.97%
Selling, General & Admin $1.235M $1.152M
YoY Change 7.2% -13.38%
% of Gross Profit 525.53% 1086.79%
Research & Development $55.00K $66.00K
YoY Change -16.67% 10.0%
% of Gross Profit 23.4% 62.26%
Depreciation & Amortization $1.000K $0.00
YoY Change
% of Gross Profit 0.43% 0.0%
Operating Expenses $1.290M $1.218M
YoY Change 5.91% -12.37%
Operating Profit -$1.055M -$1.112M
YoY Change -5.13% -15.11%
Interest Expense $34.00K -$13.00K
YoY Change -361.54% -99.34%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$1.095M -$1.125M
YoY Change -2.67% -77.04%
Income Tax $2.000K $7.000K
% Of Pretax Income
Net Earnings -$1.097M -$1.132M
YoY Change -3.09% -76.99%
Net Earnings / Revenue -309.89% -416.18%
Basic Earnings Per Share -$0.67 -$0.81
Diluted Earnings Per Share -$0.66 -$40.43K
COMMON SHARES
Basic Shares Outstanding 1.652M shares 1.400M shares
Diluted Shares Outstanding 1.652M shares

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.512M $5.990M
YoY Change -74.76% -24.65%
Cash & Equivalents $1.512M $5.990M
Short-Term Investments
Other Short-Term Assets $782.0K $911.0K
YoY Change -14.16% 333.81%
Inventory $2.213M $355.0K
Prepaid Expenses
Receivables $58.00K $134.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.565M $7.390M
YoY Change -38.23% -11.6%
LONG-TERM ASSETS
Property, Plant & Equipment $7.000K $49.00K
YoY Change -85.71% 63.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.000K $224.0K
YoY Change -97.77% 1.82%
Total Long-Term Assets $246.0K $273.0K
YoY Change -9.89% 13.75%
TOTAL ASSETS
Total Short-Term Assets $4.565M $7.390M
Total Long-Term Assets $246.0K $273.0K
Total Assets $4.811M $7.663M
YoY Change -37.22% -10.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $45.00K $172.0K
YoY Change -73.84% 72.0%
Accrued Expenses $55.00K $44.00K
YoY Change 25.0% 340.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.289M $2.007M
YoY Change 14.05% 128.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $319.0K $395.0K
YoY Change -19.24% -88.31%
Total Long-Term Liabilities $319.0K $395.0K
YoY Change -19.24% -88.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.289M $2.007M
Total Long-Term Liabilities $319.0K $395.0K
Total Liabilities $2.608M $2.402M
YoY Change 8.58% -43.62%
SHAREHOLDERS EQUITY
Retained Earnings -$63.48M
YoY Change
Common Stock $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.203M $5.261M
YoY Change
Total Liabilities & Shareholders Equity $4.811M $7.663M
YoY Change -37.22% -10.9%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.097M -$1.132M
YoY Change -3.09% -76.99%
Depreciation, Depletion And Amortization $1.000K $0.00
YoY Change
Cash From Operating Activities -$1.200M -$3.740M
YoY Change -67.91% 293.68%
INVESTING ACTIVITIES
Capital Expenditures $1.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.000K
YoY Change
NET CHANGE
Cash From Operating Activities -$1.200M -$3.740M
Cash From Investing Activities -$1.000K
Cash From Financing Activities $7.000K
Net Change In Cash -$1.201M -$3.740M
YoY Change -67.89% -913.04%
FREE CASH FLOW
Cash From Operating Activities -$1.200M -$3.740M
Capital Expenditures $1.000K
Free Cash Flow -$1.201M -$3.740M
YoY Change -67.89% 293.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001326706
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36445
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NanoVibronix, Inc
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0801232
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
525 Executive Blvd.
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Elmsford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10523
CY2023Q1 dei City Area Code
CityAreaCode
(914)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
233-3004
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
NAOV
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1662330 shares
CY2023Q1 us-gaap Cash
Cash
1512000 usd
CY2022Q4 us-gaap Cash
Cash
2713000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
58000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
782000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
712000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2213000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
2175000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
4565000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5609000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2023Q1 NAOV Severance Assets Noncurent
SeveranceAssetsNoncurent
179000 usd
CY2022Q4 NAOV Severance Assets Noncurent
SeveranceAssetsNoncurent
179000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81000 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
246000 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
270000 usd
CY2023Q1 us-gaap Assets
Assets
4811000 usd
CY2022Q4 us-gaap Assets
Assets
5879000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
45000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66000 usd
CY2023Q1 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
2189000 usd
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
2148000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
21000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
81000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2289000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2316000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
223000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
223000 usd
CY2023Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
96000 usd
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
107000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2608000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2646000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1662330 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1662330 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1641146 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1641146 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65708000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65634000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63482000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62385000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2203000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
67000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4811000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5879000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
354000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
272000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
119000 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
166000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
235000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
106000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
214000 usd
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
210000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1021000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
942000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1290000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1218000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1055000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1112000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
34000 usd
CY2023Q1 NAOV Financial Expenses Net
FinancialExpensesNet
-6000 usd
CY2022Q1 NAOV Financial Expenses Net
FinancialExpensesNet
-13000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1095000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1125000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1097000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1132000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1651936 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1399890 shares
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1097000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1132000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
5000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
4000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1102000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1136000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6314000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
86000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-6000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1132000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5262000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1097000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2203000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2203000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1097000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1132000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
67000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
86000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
2000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
49000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-66000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
70000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
681000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
180000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-21000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
85000 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
41000 usd
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
24000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-32000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1200000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1741000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1201000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1747000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2713000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7737000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1512000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5990000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
2.32 pure
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
127.9 pure
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80C_eus-gaap--NatureOfOperations_ztqtegExUtMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_828_zj4fZT6dRjy8">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_znJR7mZkJ1p2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zQ6YYHtR2OY8">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
7000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
6000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
15726 shares
CY2022Q1 us-gaap Share Price
SharePrice
15.56
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
15.56
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
220412 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
248467 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
354000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
272000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10 pure
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
18000 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
7000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
54000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
57000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
55000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3000 usd
CY2023Q1 NAOV Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
2000 usd
CY2022Q1 NAOV Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
2000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2021Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3000000 usd
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1500250 usd
CY2023Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
1432000 usd
CY2023Q1 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
68250 usd
CY2023Q1 us-gaap Legal Fees
LegalFees
76034000 usd

Files In Submission

Name View Source Status
0001493152-23-017233-index-headers.html Edgar Link pending
0001493152-23-017233-index.html Edgar Link pending
0001493152-23-017233.txt Edgar Link pending
0001493152-23-017233-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
naov-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
naov-20230331_cal.xml Edgar Link unprocessable
naov-20230331_def.xml Edgar Link unprocessable
naov-20230331_lab.xml Edgar Link unprocessable
naov-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending